Angiostatic steroids. Method of discovery and mechanism of action
about
Combination oral antiangiogenic therapy with thalidomide and sulindac inhibits tumour growth in rabbitsAntiangiogenic gene therapy of cancer: recent developmentsAn in vivo neovascularization assay for screening regulators of angiogenesis and assessing their effects on pre-existing vessels.Changing therapeutic paradigms for exudative age-related macular degeneration: antiangiogenic agents and photodynamic therapy.Anti-angiogenic therapy of proliferative diabetic retinopathy.Choroidal neovascular membrane inhibition in a laser treated rat model with intraocular sustained release triamcinolone acetonide microimplants.Future pharmacological treatment options for nonexudative and exudative age-related macular degeneration.Current and future pharmacological intervention for diabetic retinopathy.A review of drug options in age-related macular degeneration therapy and potential new agents.Role of steroids in the management of diabetic macular edema and proliferative diabetic retinopathy.Steroid-resistant lymphatic remodeling in chronically inflamed mouse airwaysDevelopment and validation of a fast and sensitive bioanalytical method for the quantitative determination of glucocorticoids--quantitative measurement of dexamethasone in rabbit ocular matrices by liquid chromatography tandem mass spectrometry.Glucocorticoid-mediated inhibition of angiogenic changes in human endothelial cells is not caused by reductions in cell proliferation or migrationPatterns of expression of vascular endothelial growth factor (VEGF) and VEGF receptors in mice suggest a role in hormonally regulated angiogenesis.Preventing local regeneration of glucocorticoids by 11beta-hydroxysteroid dehydrogenase type 1 enhances angiogenesis.Gastric antral vascular ectasia: maintenance treatment with oestrogen-progesterone.Inhibition of proliferation, migration and proteolysis contribute to corticosterone-mediated inhibition of angiogenesisAngiogenesis and rheumatoid arthritis: pathogenic and therapeutic implicationsTreatment of central retinal vein occlusion with triamcinolone acetonide: an optical coherence tomography study.Intravitreal triamcinolone with photodynamic therapy for subfoveal choroidal neovascularisation in age related macular degeneration.Pharmacologic uncoupling of angiogenesis and inflammation during initiation of pathological corneal neovascularizationDifferential effects of angiostatic steroids and dexamethasone on angiogenesis and cytokine levels in rat sponge implantsDexamethasone inhibits interleukin-1beta-induced corneal neovascularization: role of nuclear factor-kappaB-activated stromal cells in inflammatory angiogenesis.Larger therapeutic window for steroid versus VEGF-A inhibitor in inflammatory angiogenesis: surprisingly similar impact on leukocyte infiltration.Angiogenesis inhibition suppresses collagen arthritis.Expression of vascular endothelial growth factor (VEGF) and its mRNA in uterine cervical cancers.Therapeutic manipulation of glucocorticoid metabolism in cardiovascular diseasePlasticity of airway lymphatics in development and disease.Potential inhibitory effect of LASSBio-596, a new thalidomide hybrid, on inflammatory corneal angiogenesis in rabbits.Inhibition of tumor angiogenesis.Tumour vasculature--a potential therapeutic target.Additive Effect of Oral Steroid with Topical Nonsteroidal Anti-inflammatory Drug for Preventing Cystoid Macular Edema after Cataract Surgery in Patients with Epiretinal Membrane.Safer topical treatment for inflammation using 5α-tetrahydrocorticosterone in mouse models.Effects of triamcinolone acetonide on vessels of the posterior segment of the eye.Glucocorticoids exert direct toxicity on microvasculature: analysis of cell death mechanisms.Inhibition of angiogenesis and tumor growth in the brain. Suppression of endothelial cell turnover by penicillamine and the depletion of copper, an angiogenic cofactor.Steroid inhibition of neural microvessel morphogenesis in vitro: receptor mediation and astroglial dependence.Determination of incidence and risk factors for postsclerotherapy telangiectatic matting of the lower extremity: a retrospective analysis.Effect of Adding Dexamethasone to Continued Ranibizumab Treatment in Patients With Persistent Diabetic Macular Edema: A DRCR Network Phase 2 Randomized Clinical Trial.Species-specific regulation of angiogenesis by glucocorticoids reveals contrasting effects on inflammatory and angiogenic pathways.
P2860
Q24650329-1E0FDC79-A80C-406B-ABD2-22821836971BQ24803786-272B9C44-CE3D-4F4E-9751-B05CFA2A216FQ30528295-0FAF566C-743B-41A1-B18C-61573D75C636Q30642886-89653291-2800-4D91-9DD2-AB4DD888F45EQ30666418-611C3042-7CF3-4016-8E39-C9CB803C6836Q31150795-10058E3B-4698-43A7-92B2-9E9B9187B06CQ33212693-9D06D926-8AF7-41EE-B412-4697C5A8E6F8Q33216425-8A952559-EC71-41AB-9C3A-C6C10071A6BCQ33263803-FC64E190-F308-4C60-8B32-1ACA455CC90FQ33431322-3A62AA11-F140-40B8-A61B-AD683C425457Q33703842-C2B22F78-639D-4743-A389-3426664833DEQ33782714-F28B6909-B2DD-4357-976D-6E7BBDEFAA4EQ33789118-9B81541D-757A-4E9C-8866-69ADA487DB22Q33900066-EB5A570A-592C-4E82-AAD6-031B0DD6950EQ33922773-139D47F6-0D25-459B-BCA8-9B17E046D73CQ34395377-7724DE47-65C2-4572-B71D-D122D0A78895Q34441751-0D1F4D98-5965-4FD7-81B8-59B8402CEC03Q35327839-4D6A5F2C-F3E9-4CAA-B194-E360E46C229EQ35563022-9AA2C349-3D0F-48CE-A8A6-8193F8AB52A6Q35591813-3CD667BB-6144-4B11-8D7A-E4DBC7D25FFFQ35639944-DC9B7873-8EEA-4777-939D-B212042FB30BQ35874063-94B21C55-C772-41B1-B512-8738EEAFFC13Q35963152-B62752B1-DA09-46AB-BFF4-CA180471C3CAQ36065917-820934AC-D93D-4310-8A4C-C732446B9C18Q36231174-868FB0AB-F92E-46C1-A977-7E90FE8CDC04Q36617680-2F15321C-4F5F-4D30-B36C-565FE47CD960Q37230796-DB9E83FE-ED81-4DFF-85C3-18195A10AC17Q37639260-6302E4E8-448B-41C8-85D7-CBD1DBFE6C9FQ40047647-34BB5A81-FAB7-4270-8A3D-DB1E5D9E11F7Q40394899-0A3D7210-8B4F-4CC0-8441-E533B77C8D88Q40403280-3B8DCFD7-EDE4-448B-A46F-4413A9A8C37BQ42262074-59BB5A4D-5E2C-4F26-8960-9E1B1CBA6D0EQ42317457-36F4299E-147D-4845-BA09-8AA33184EA7FQ42464404-2CB55645-AD8B-4CF7-903F-19D000085752Q42703437-B5DD821A-0E95-4D06-BCC5-CFB002D511C1Q42773874-3248B785-61AC-4D2A-87CE-F6AFECC00DF4Q43670406-A22C43C5-D709-42F3-8B20-BEEE6216F598Q45075334-39188FAC-450C-42AD-B7EC-2616194A0585Q45305404-83A3E982-8A04-4F0A-A694-A8DB20C4C636Q49980134-152D0464-9994-461C-A34D-C7D560FB0609
P2860
Angiostatic steroids. Method of discovery and mechanism of action
description
1987 nî lūn-bûn
@nan
1987 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1987 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1987年の論文
@ja
1987年論文
@yue
1987年論文
@zh-hant
1987年論文
@zh-hk
1987年論文
@zh-mo
1987年論文
@zh-tw
1987年论文
@wuu
name
Angiostatic steroids. Method of discovery and mechanism of action
@ast
Angiostatic steroids. Method of discovery and mechanism of action
@en
Angiostatic steroids. Method of discovery and mechanism of action
@nl
type
label
Angiostatic steroids. Method of discovery and mechanism of action
@ast
Angiostatic steroids. Method of discovery and mechanism of action
@en
Angiostatic steroids. Method of discovery and mechanism of action
@nl
prefLabel
Angiostatic steroids. Method of discovery and mechanism of action
@ast
Angiostatic steroids. Method of discovery and mechanism of action
@en
Angiostatic steroids. Method of discovery and mechanism of action
@nl
P2860
P1433
P1476
Angiostatic steroids. Method of discovery and mechanism of action
@en
P2093
P2860
P304
P356
10.1097/00000658-198709000-00016
P407
P577
1987-09-01T00:00:00Z